CITI RECOGNISED AS BEST INTERNATIONAL BANK IN SINGAPORE IN RECORD HAUL AT THE EUROMONEY AWARDS FOR EXCELLENCE 2025
CEO Jane Fraser named Banker of the Year
Over 50 awards recognize Citi's global network
SINGAPORE, July 24, 2025 /PRNewswire/ -- Citi has been named the Best International Bank and Best Investment Bank for M&A in Singapore at the Euromoney Awards for Excellence 2025. The bank won 17 awards across Asia, including the Best International Bank award in six markets and Asia's Best Investment Bank for DCM, a strong testament to the leadership and strength of the business within the region.
In total, Citi won a record 52 global, regional and local market awards from Euromoney, including CEO Jane Fraser's "Banker of The Year" award, at the annual Euromoney Awards for Excellence 2025 event held in London.
The Banker of the Year award recognized Jane's unique leadership style and ability to influence significant change across the bank, highlighting Citi's record financial performance in recent quarters and across each of its five businesses.
"Euromoney names Jane Fraser its banker of the year for her decisive action to reshape Citi into a simpler and more coherent bank, bringing the firm new business momentum over the past year," said Euromoney in the editorial write-up announcing the award.
Fraser said, "These awards are a testament to the extraordinary dedication of our colleagues around the world. Their hard work, innovation and commitment to our clients are driving Citi forward. I'm proud of the progress we're making against our strategy — and this recognition affirms that we're on the right path."
"Citi has been in Singapore since 1902 and has grown into a full-service partner for clients here. As Euromoney's Best International Bank in Singapore, we are proud to provide our clients with access to our international network and expertise in Banking, Markets, Services, and Wealth, and remain committed to serving our clients and meeting their needs," said Tibor Pandi, Singapore Citi Country Officer and Banking Head.
Euromoney, a leading global financial markets magazine, recognizes the best in banking across key areas that are most important to a bank's key stakeholders, clients, board and executive management teams. The period of consideration for the awards was the 2024 calendar year.
In its 30th edition, the 2025 Euromoney Awards recognized Citi as:
The World's Best Investment Bank for Financing
The World's Best Investment Bank for Debt Capital Markets (DCM)
The World's Best for Research
The World's Best Digital Bank for Large Corporates
Asia's Best Investment Bank for DCM
About Citi Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.
Additional information may be found at www.citigroup.com | X: @Citi | LinkedIn: www.linkedin.com/company/citi | YouTube: www.youtube.com/citi | Facebook: www.facebook.com/citi
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/citi-recognised-as-best-international-bank-in-singapore-in-record-haul-at-the-euromoney-awards-for-excellence-2025-302512971.html
SOURCE Citi
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 minutes ago
- Associated Press
Asian shares track rally on Wall Street that won back most of Friday's wipeout
BANGKOK (AP) — Asian shares advanced on Tuesday, following U.S. stocks higher after they won back most of their sharp loss from last week. Investors appeared to have recovered some confidence after worries over how President Donald Trump's tariffs may be punishing the economy sent a shudder through Wall Street last week. At the same time, a stunningly weak U.S. jobs report Friday raised expectations that the Federal Reserve will cut interest rates at its next meeting in September, potentially a plus for markets. This week's highlights will likely include earnings reports from The Walt Disney Co., McDonald's and Caterpillar, along with updates on U.S. business activity. In Asian trading, Tokyo's Nikkei 225 index gained 0.6% to 40,515.81, while the Kospi in South Korea jumped 1.4% to 3,192.57. In Hong Kong, the Hang Seng rose 0.3% to 24,799.67. The Shanghai Composite index was up 0.5% at 3,602.13. Australia's S&P/ASX 200 jumped 1.1% to 8,759.90, while the SET in Thailand also gained 1.1%. India's Sensex was the sole outlier, losing 0.5% on concerns over trade tensions with the United States, with the Trump administration insisting on cutbacks in oil purchases from Russia. India has indicated that it will continue buying oil from Russia, saying its relationship with Moscow was 'steady and time-tested,' and that its stance on securing its energy needs is guided by the availability of oil in the markets and prevailing global circumstances. 'Trump's threats of 'substantial' tariff hikes on account of imports of Russian crude pose a quagmire for India,' Mizuho Bank said in a commentary. 'Between exacerbated U.S.-imposed geo-economic headwinds and financial/macro setbacks from Russian oil advantages lost, pain will be hard to avert.' On Monday, the S&P 500 jumped 1.5% to 6,329.94. The Dow Jones Industrial Average climbed 1.3%, or 585.06 points, to 44,173.64. The Nasdaq composite leaped 2% to 21,053.58. Idexx Laboratories helped Wall Street recover from its worst day since May, soaring 27.5% after the seller of veterinary instruments and other health care products reported a stronger profit for the spring than analysts expected. The pressure is on U.S. companies to deliver bigger profits after their stock prices shot to record after record recently. Reports from big U.S. companies have largely come in better than expected and could help steady a U.S. stock market that may have been due for some turbulence. A jump in stock prices from a low point in April had raised criticism that the broad market had become too expensive. Tyson Foods likewise delivered a bigger-than-expected profit for the latest quarter, and the company behind the Jimmy Dean and Hillshire Farms brands rose 2.4%. They helped make up for a nearly 3% loss for Berkshire Hathaway after Warren Buffett's company reported a drop in profit for its latest quarter from a year earlier. The drop-off was due in part to the falling value of its investment in Kraft Heinz. American Eagle Outfitters jumped 23.6% after Trump weighed in on the debate surrounding the retailer's advertisements, which highlight actor Sydney Sweeney's great jeans. Some critics thought the reference to the blonde-haired and blue-eyed actor's 'great genes' may be extolling a narrow set of beauty standards. 'Go get 'em Sydney!' Trump said on his social media network. Wayfair climbed 12.7% after the retailer of furniture and home decor said accelerating growth helped it make more in profit and revenue during the spring than analysts expected. Tesla rose 2.2% after awarding CEO Elon Musk 96 million shares of restricted stock valued at approximately $29 billion. The move could alleviate worries that Musk may leave the company. In other dealings early Tuesday, U.S. benchmark crude oil shed 9 cents to $66.20 per barrel while Brent crude, the international standard, gave up 8 cents to $68.68 per barrel. The U.S. dollar was unchanged at 147.09 Japanese yen. The euro slipped to $1.1555 from $1.1573. ___ AP Business Writers Stan Choe and Matt Ott contributed.
Bloomberg
4 minutes ago
- Bloomberg
Aramco Profit Falls for a 10th Quarter as Weak Oil Hits Earnings
Saudi Aramco reported a decline in profit for a 10th straight quarter as lower oil prices outweighed the impact of higher production. Net income attributable to shareholders dropped 19% to 85.63 billion riyals ($22.8 billion) in the second quarter from a year earlier, according to a statement Tuesday. That missed analysts' estimates compiled by Bloomberg. Free cash flow again failed to cover the dividend.
Yahoo
31 minutes ago
- Yahoo
Asian Market Value Picks: 3 Companies That May Be Trading Below Intrinsic Estimates
Amidst global economic uncertainties and fluctuating trade policies, Asian markets have shown resilience, with varying impacts on indices across the region. This environment presents opportunities for discerning investors to explore stocks that may be trading below their intrinsic value, particularly those with strong fundamentals and potential for growth despite external pressures. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xi'an NovaStar Tech (SZSE:301589) CN¥155.51 CN¥309.46 49.7% SpiderPlus (TSE:4192) ¥506.00 ¥997.79 49.3% Ningbo Sanxing Medical ElectricLtd (SHSE:601567) CN¥22.88 CN¥45.72 50% Nanya Technology (TWSE:2408) NT$43.75 NT$87.13 49.8% Nan Ya Printed Circuit Board (TWSE:8046) NT$176.50 NT$350.51 49.6% Insource (TSE:6200) ¥926.00 ¥1843.53 49.8% H.U. Group Holdings (TSE:4544) ¥3254.00 ¥6446.96 49.5% Elan (TSE:6099) ¥850.00 ¥1696.06 49.9% cottaLTD (TSE:3359) ¥441.00 ¥871.25 49.4% Astroscale Holdings (TSE:186A) ¥676.00 ¥1333.68 49.3% Click here to see the full list of 274 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Beijing HyperStrong Technology Overview: Beijing HyperStrong Technology Co., Ltd. designs, develops, integrates, and operates energy storage power stations across China, Europe, North America, and Australia with a market cap of CN¥16.64 billion. Operations: The company's revenue segments include the design, development, integration, and operation of energy storage power stations across its key markets in China, Europe, North America, and Australia. Estimated Discount To Fair Value: 37.2% Beijing HyperStrong Technology is trading at CN¥92.37, significantly below its estimated fair value of CN¥147.06, suggesting it may be undervalued based on cash flows. Its revenue and earnings are forecast to grow over 30% annually, outpacing the Chinese market's growth rates. However, its dividend yield of 1.19% is not well covered by free cash flows. Recent innovations like the HyperBlock M enhance its competitive edge in energy storage solutions through modularity and efficiency improvements. Upon reviewing our latest growth report, Beijing HyperStrong Technology's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of Beijing HyperStrong Technology stock in this financial health report. Shenzhen KSTAR Science and Technology Overview: Shenzhen KSTAR Science and Technology Co., Ltd. operates in the technology sector, focusing on power electronics and renewable energy solutions, with a market cap of CN¥13.86 billion. Operations: Unfortunately, the provided text does not contain specific revenue segment information for Shenzhen KSTAR Science and Technology Co., Ltd. Estimated Discount To Fair Value: 48.5% Shenzhen KSTAR Science and Technology is trading at CN¥23.8, well below its estimated fair value of CN¥46.24, indicating potential undervaluation based on cash flows. The company's revenue is projected to grow 22.3% annually, surpassing the Chinese market's average growth rate. Despite a forecasted earnings growth of 32.4%, profit margins have declined from last year, and the dividend track record remains unstable with recent reductions in payouts for 2024 dividends. The growth report we've compiled suggests that Shenzhen KSTAR Science and Technology's future prospects could be on the up. Click here to discover the nuances of Shenzhen KSTAR Science and Technology with our detailed financial health report. Qingdao Baheal Medical Overview: Qingdao Baheal Medical INC. is involved in the research, development, production, wholesale, and retail of pharmaceutical products across China, the United States, Hong Kong, and the United Kingdom with a market cap of CN¥11.77 billion. Operations: Qingdao Baheal Medical INC. generates revenue through its activities in the research, development, production, wholesale, and retail sectors of pharmaceutical products across several international markets including China, the United States, Hong Kong, and the United Kingdom. Estimated Discount To Fair Value: 18.5% Qingdao Baheal Medical, trading at CN¥22.39, is priced below its fair value estimate of CN¥27.46, reflecting potential undervaluation based on cash flows. Despite a volatile share price recently, earnings are projected to grow significantly at 20.05% annually over the next three years, although this lags behind the broader Chinese market's growth rate. The company affirmed a dividend payout for 2024, which may appeal to income-focused investors amid stable revenue growth projections of 13% per year. In light of our recent growth report, it seems possible that Qingdao Baheal Medical's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Qingdao Baheal Medical. Turning Ideas Into Actions Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 271 more companies for you to here to unveil our expertly curated list of 274 Undervalued Asian Stocks Based On Cash Flows. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688411 SZSE:002518 and SZSE:301015. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
